Date: 2014-07-08
Type of information: Grant
Company: Biotie Therapies (Finland)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: $2 million
Funding type: grant
Planned used: MJFF will fund an 80 patient, Phase 2a, randomized, double-blind, placebo-controlled trial of 16 weeks duration in patients with Parkinson\'s disease dementia. In addition to assessing safety and tolerability, the main focus of the trial will be to establish efficacy of SYN120 on cognition using the Cognitive Drug Research (CDR) Computerized Cognition Battery as the primary efficacy endpoint. This trial, which is expected to begin in H2 2014, will be conducted by the Parkinson Study Group (PSG) at approximately 10 US sites specializing in cognitive dysfunction in Parkinson\'s disease. Biotie and the PSG will share responsibility to design and execute this study.
Others: * On July 8, 2014, Biotie Therapies announced that the company has signed a $ 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson\'s disease patients with dementia. SYN120 is a dual antagonist of 5-HT6 and 5-HT2a receptors and these two distinct modes of action could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. Biotie retains the rights to SYN120 and will be able to use data from the MJFF-funded study for any future regulatory submission.
Therapeutic area: Neurodegenerative diseases
